{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:20:36Z","timestamp":1787314836853,"version":"build-2736575974"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The combination of strengthening Qi and eliminating pathogens is an available therapeutic principle in traditional Chinese medicine (TCM) for primary liver cancer (PLC) at middle-advanced stage. However, there is a lack of reasonable evidence to support the proper application of this therapeutic principle. This meta-analysis aims to evaluate the efficacy and safety of Chinese medicinal formulas (CMFs), including two subgroup analyses of the principle of strengthening Qi and eliminating pathogens.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Method:<\/jats:bold>\n                    Clinical trials were obtained through searching of EMBASE, Web of Science, PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journal Database, Chinese Biomedical Literature Database, and two clinical trial registries. The randomized controlled trials with the combination of CMFs and transcatheter arterial chemoembolization (TACE) in the experiment group were acceptable, in contrast to the TACE alone in the control group. The statistics analysis was performed on Review Manager 5.4.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of eligible 24 trials were accessed in this work. Overall, CMFs could improve the survival duration of 6\u00a0months, 1 year, and 2 years, Karnofsky Performance Status, tumor objective response rate (ORR), AFP, and symptom. In the subgroup analysis, trials complying with the principle of single strengthening Qi did not show any significant difference in increasing tumor ORR. Meanwhile, the principle of combined strengthening Qi and eliminating pathogens was uncertain in improving symptoms and 1-year and 2-year survival time. In addition, the outcome indexes of ALT and AST were heterogeneous. In last, the total occurrence of adverse events could not be reduced via using CMFs. Patients treated with CMFs exhibited liver injury, fever, and white blood cell decline, with mild events occurring more frequently and severe events occurring less.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    CMFs are an effective treatment method to cure PLC at the middle-advanced stage. Adopting the principle of single strengthening Qi presents better efficacy in the long term by prolonging the survival duration. Following the principle of combined strengthening Qi and eliminating pathogens could be more beneficial to patients in short term by lessening the tumor size. CMFs have the advantage of reducing certain serious adverse events.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.714287","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:38:08Z","timestamp":1635295088000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["The Therapeutic Principle of Combined Strengthening Qi and Eliminating Pathogens in Treating Middle-Advanced Primary Liver Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Yingqi","family":"She","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingquan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihua","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaobo","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/jso.24518","article-title":"Global trends in the burden of liver cancer","volume":"115","author":"Are","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4254\/wjh.v7.i12.1708","article-title":"Hepatocellular carcinoma in Asia: Prevention strategy and planning","volume":"7","author":"Ashtari","year":"2015","journal-title":"World J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1007\/s00270-019-02325-3","article-title":"Monitoring Liver Function of Patients Undergoing Transarterial Chemoembolization (TACE) by a 13C Breath Test (LiMAx)","volume":"42","author":"Barzakova","year":"2019","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1038\/cddis.2013.528","article-title":"The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression","volume":"5","author":"Becker","year":"2014","journal-title":"Cell Death Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1016\/j.jhep.2015.02.007","article-title":"Liver cancer: Approaching a personalized care","volume":"62","author":"Bruix","year":"2015","journal-title":"J. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"112465","DOI":"10.1016\/j.jep.2019.112465","article-title":"Anti-tumor activity and linear-diarylheptanoids of herbal couple Curcumae Rhizoma-Sparganii Rhizoma and the single herbs","volume":"250","author":"Chang","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"104871","DOI":"10.1016\/j.phrs.2020.104871","article-title":"Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3","volume":"158","author":"Chen","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B10","first-page":"2657","article-title":"Forty-Two Cases with Primary Liver Cancer Treated with Modified Liver-Benefiting and Distention-Reducing Decoction Combined with Interventional Therapy","volume":"35","author":"Cheng","year":"2015","journal-title":"Henan Tradit Chin. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"7302","DOI":"10.7150\/jca.49554","article-title":"Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer","volume":"11","author":"Cheng","year":"2020","journal-title":"J. Cancer"},{"key":"B12","first-page":"16","article-title":"The Effectiveness of Liver-soothing and Spleen-strengthening Traditional Chinese Medicine Combined with Intra-arteriaI Infusion of Chemical Medicine for Advanced Primary Hepatocellular Cancer Patients","volume":"17","author":"Chi","year":"2010","journal-title":"Chin. J. Inf. TCM"},{"key":"B13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3390\/cancers11040509","article-title":"Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization","volume":"11","author":"Chon","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3969\/j.issn.1002-266X.2014.16.024","article-title":"Clinical Observation of oral Jianpiyigan Prescription Combined with Hepatic Arterial Chemotherapy Embolism in Elderly Primary Liver Cancer","volume":"54","author":"Deng","year":"2014","journal-title":"Shandong Med. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3969\/j.issn.1007-3205.2012.06.024","article-title":"Clinical Observation of Fuzheng Decoction Combined with Transcatheter Arterial Chemoembolization in middle-advanced Hepatocellular Carcinoma","volume":"33","author":"Ding","year":"2012","journal-title":"J. Hebei Med. Univ."},{"key":"B16","first-page":"3895","article-title":"Clinical Observation of Biejiajian Pill with Transcatheter Arterial Chemoembolization in Hepatic Fibrosis","volume":"38","author":"Du","year":"2018","journal-title":"Chin. J. Gerontol."},{"key":"B17","first-page":"95","article-title":"Clinical Observation of Transcatheter Hepatic Arterial Chemoembolization Combined with Chinese Herbal Medicine in Treating 42 Cases with Primary Liver Cancer","volume":"24","author":"Feng","year":"2015","journal-title":"Chin. J. Ethomed Ethnopharm"},{"key":"B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jhep.2017.03.007","article-title":"The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy","volume":"67","author":"Galle","year":"2017","journal-title":"J. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S0168827818302150","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000333280","article-title":"Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia","author":"Han","year":"2011","journal-title":"Oncology"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/17441692.2018.1534254","article-title":"Prevalence of traditional, complementary, and alternative medicine use by cancer patients in low income and lower-middle income countries","volume":"14","author":"Hill","year":"2019","journal-title":"Glob. Public Health"},{"key":"B23","first-page":"1721","article-title":"Recent Clinical Observation of Shenyi Capsule with Cidan Capsule in Chemoembolizeing the Advanced Primary Liver Cancer","volume":"36","author":"Huang","year":"2009","journal-title":"Liaoning J. Tradit Chin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.4254\/wjh.v6.i12.844","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques","volume":"6","author":"Imai","year":"2014","journal-title":"World J. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1016\/j.jceh.2016.03.006","article-title":"Advances in Management of Hepatocellular Carcinoma","volume":"17","author":"Intaraprasong","year":"2016","journal-title":"Asian Pac. J. Clin. Cancer Prev."},{"key":"B26","first-page":"80","article-title":"Clinical Observation on Xiaoyao Powder Combined with Intervention of Hepatocellular Carcinoma of Liver-depression and Spleen-deficiency Syndrome","volume":"14","author":"Ji","year":"2012","journal-title":"Liaoning J. Tradit Chin. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"113571","DOI":"10.1016\/j.jep.2020.113571","article-title":"Sparganii Rhizoma: A review of traditional clinical application, processing, phytochemistry, pharmacology, and toxicity","volume":"268","author":"Jia","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"B28","first-page":"4214","article-title":"Short-term Curative and Plasma Angiogenic Responses to Fuhe Beihua Decoction with Transcatheter Arterial Chemoembolization in Primary Liver Cancer Patients with Liver Depression and Spleen Deficiency Syndrome","volume":"23","author":"Jiang","year":"2020","journal-title":"Chin. J. Gerontol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/1472-6882-14-362","article-title":"The quality of reports of randomized clinical trials on traditional Chinese medicine treatments: a systematic review of articles indexed in the China National Knowledge Infrastructure database from 2005 to 2012","volume":"14","author":"Li","year":"2014","journal-title":"BMC Complement. Altern. Med."},{"key":"B30","first-page":"104","article-title":"Clinical Observation of Applying TACE Combined with Traditional Chinese Medicine in thet Treatment of Primary Liver Cancer during Medium and Advanced Stage","volume":"35","author":"Li","year":"2017","journal-title":"J. Sichuan Tradit Chin. Med."},{"key":"B31","first-page":"742","article-title":"Clinical Study of Transcatheter Hepatic Arterial Chemoembolization Combined with Chinese Herbal Medicine in Primary Liver Cancer","volume":"31","author":"Li","year":"2011","journal-title":"J. Nanjing Med. Univ."},{"key":"B32","first-page":"518","article-title":"Thirty-Two Cases with Primary Liver Cancer Treated with WD\u20102 Combined with Intervention of Hepatocellular Carcinoma","volume":"34","author":"Liu","year":"2013","journal-title":"Shanxi J. Tradit Chin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"112687","DOI":"10.1016\/j.jep.2020.112687","article-title":"Compound-based Chinese medicine formula: From discovery to compatibility mechanism","volume":"254","author":"Luan","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/hpb.12487","article-title":"Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma","volume":"17","author":"Mason","year":"2015","journal-title":"HPB (Oxford)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s12885-019-5989-2","article-title":"Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study","volume":"19","author":"Miksad","year":"2019","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.2159010.3322\/caac.21637","article-title":"Cancer statistics for adolescents and young adults, 2020","volume":"70","author":"Miller","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B37","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/bjc.1982.83","article-title":"WHO Handbook for Reporting Cancer Treatment","volume":"45","author":"Palmer","year":"1982","journal-title":"Br. J. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.3390\/ijms21145011","article-title":"Potential Hepatotoxins Found in Herbal Medicinal Products: A Systematic Review","volume":"21","author":"Quan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","article-title":"Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization","volume":"37","author":"Raoul","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"B42","first-page":"18","article-title":"Dujieqing Oral Liquid Combined Hepatic Arterial Chemotherapy Embolism(TACE) in Treatment of Advanced Primary Liver Cancer","volume":"15","author":"Rong","year":"2013","journal-title":"Liaoning J. Tradit Chin. Med."},{"key":"B43","first-page":"44","article-title":"Clinical Study on Gexia Zhuyu Tang for Advanced Liver Cancer after Precise TACE","volume":"52","author":"Shen","year":"2020","journal-title":"J. New Chin. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jhep.2015.02.010","article-title":"Transarterial chemoembolization: Modalities, indication, and patient selection","volume":"62","author":"Sieghart","year":"2015","journal-title":"J. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.clon.2019.05.016","article-title":"Chinese Medicine in Cancer Treatment - How is it Practised in the East and the West","volume":"31","author":"So","year":"2019","journal-title":"Clin. Oncol. (R Coll. Radiol."},{"key":"B46","first-page":"22","article-title":"Clinical Research of Wenyang Jiedu Formula with TACE in the Treatment of Advanced Primary Hepatic Carcinoma","volume":"40","author":"Song","year":"2017","journal-title":"J. Yunnan Univ. Tradit Chin. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A. Cancer J. Clin."},{"key":"B48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00261-017-1209-1","article-title":"Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis","volume":"43","author":"Tang","year":"2018","journal-title":"Abdom. Radiol. (Ny)"},{"key":"B49","first-page":"906","article-title":"Clinical Observation of Aitongxiao Formula with TACE in the Treatment of Middle-advanced Primary liver cancer","volume":"26","author":"Tang","year":"2015","journal-title":"Lishizhen Med. Mater. Med. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"B51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"key":"B52","first-page":"114","article-title":"Clinical Observation of Modified Bazhen decoction on Adverse Reactions after TACE in Primary Liver Cancer","volume":"58","author":"Wang","year":"2020","journal-title":"Chin Mod. Doctor"},{"key":"B53","first-page":"5827","article-title":"The Effect of Yangzhengxiaoji Capsule on Tumor Marker and Quality of Life in Primary Liver Cancer Patients","volume":"35","author":"Wang","year":"2015","journal-title":"Chin. J. Gerontol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/jphp.12706","article-title":"Astragaloside II sensitizes human hepatocellular carcinoma cells to 5-fluorouracil via suppression of autophagy","volume":"69","author":"Wang","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"B55","first-page":"1121","article-title":"Clinical Study on Treating Primary Hepatic Carcinoma with Syndrome of Stagnation of Liver Qi and Spleen Deficiency with Combination of Oral Ganxi Tablets and Arsenic Trioxide via Transcatheter Arterial Chemoembolization","volume":"31","author":"Wang","year":"2016","journal-title":"Chin. J. Tradit Chin. Med. Pharm."},{"key":"B56","first-page":"151","article-title":"Short-term Clinical Observation of Fuzheng Quxie Yiai Recipe Combined with TACE in the Treatment of Patients with Advanced Primary Liver Cancer","volume":"16","author":"Wang","year":"2020","journal-title":"Asia-pacific Tradit Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1875-5364(17)30041-9","article-title":"Impact of Qi-invigorating traditional Chinese medicines on intestinal flora: A basis for rational choice of prebiotics","volume":"15","author":"Wang","year":"2017","journal-title":"Chin. J. Nat. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"109570","DOI":"10.1016\/j.biopha.2019.109570","article-title":"Antitumor effects of immunity-enhancing traditional Chinese medicine","volume":"121","author":"Wang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.csbj.2018.10.015","article-title":"Development of Fangjiomics for Systems Elucidation of Synergistic Mechanism Underlying Combination Therapy","volume":"16","author":"Wei","year":"2018","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B61","first-page":"541","article-title":"Clinical Observation on 68 Cases of Terminal-stage Liver Cancer Treated with TACE Combined Soothing Liver and Invigorating Spleen","volume":"39","author":"Ye","year":"2015","journal-title":"J. Zhejiang Chin. Med. Univ."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jpain.2018.04.015","article-title":"Pharmacopuncture With Scolopendra subspinipes Suppresses Mechanical Allodynia in Oxaliplatin-Induced Neuropathic Mice and Potentiates Clonidine-induced Anti-allodynia Without Hypotension or Motor Impairment","volume":"19","author":"Yoon","year":"2018","journal-title":"J. Pain"},{"key":"B63","doi-asserted-by":"publisher","first-page":"108812","DOI":"10.1016\/j.biopha.2019.108812","article-title":"Molecular targets of \u03b2-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review","volume":"114","author":"Zhai","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1186\/s12885-019-6011-8","article-title":"The prognostic significance of serum gamma-glutamyltransferase levels and AST\/ALT in primary hepatic carcinoma","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"B65","first-page":"164","article-title":"The efficacy of Sanjinshusan Decoction Combined with TACE on Middle-Late Liver Cancer","volume":"30","author":"Zhang","year":"2020","journal-title":"Chin. J. Liv Integr. Tradit West. Med."},{"key":"B66","first-page":"235","article-title":"Clinical Study of Guben Yiliu \u2161 Combined with Chemicals Arterial Perfusion for Advanced Hepatoma of 58 Cases","volume":"48","author":"Zhang","year":"2007","journal-title":"J. Tradit Chin. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jncc.2020.12.001","article-title":"Cancer incidence and mortality in China, 2015","volume":"1","author":"Zhang","year":"2021","journal-title":"J. Natl. Cancer Cent."},{"key":"B68","first-page":"111","article-title":"Clinical Research of Clearing Liver-fire for Removing Blood Stasis Prescription Combined with TACE in the Treatment of Patients with Advanced Primary Liver Cancer","volume":"35","author":"Zhang","year":"2017","journal-title":"J. Sichuan Tradit Chin. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.curtheres.2010.02.001","article-title":"The reporting quality, scientific rigor, and ethics of randomized placebo-controlled trials of traditional Chinese medicine compound formulations and the differences between Chinese and non-Chinese trials","volume":"71","author":"Zhong","year":"2010","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"B70","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5009\/gnl15257","article-title":"Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region","volume":"10","author":"Zhu","year":"2016","journal-title":"Gut Liver"}],"updated-by":[{"DOI":"10.3389\/fphar.2022.846668","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.714287\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T21:19:54Z","timestamp":1643836794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.714287\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":69,"alternative-id":["10.3389\/fphar.2021.714287"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.714287","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"article-number":"714287"}}